MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Molina Healthcare Inc (MOH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is facing significant challenges, including poor financial performance, downgrades from analysts, and a lack of positive catalysts. The technical indicators and options data do not suggest a strong entry point, and the company's recent financials indicate declining profitability. Given the investor's profile and the current data, it is better to hold off on investing in this stock.
The technical indicators for MOH show a bearish trend. The moving averages are aligned negatively (SMA_200 > SMA_20 > SMA_5), indicating downward momentum. The RSI is neutral at 47.841, and the MACD histogram is positive at 1.238, but this is not strong enough to counteract the bearish moving averages. Key resistance levels are at 155.33 and 163.753, while support levels are at 128.064 and 119.641.
NULL identified. The MACD is positive, but this is insufficient to counteract the overall negative sentiment.
Poor Q4 financial performance with a significant drop in net income (-163.75% YoY) and EPS (-171.17% YoY).
Multiple analyst downgrades with reduced price targets, citing concerns over Medicaid and Medicare pressures, low-margin business risks, and poor guidance for
Legal investigation into adverse medical cost trends.
Bearish technical indicators with negative moving averages.
Molina Healthcare's Q4 2025 financials show revenue growth of 8.34% YoY to $11.38 billion. However, net income dropped to -$160 million (-163.75% YoY), and EPS fell to -3.16 (-171.17% YoY). Gross margin also declined to 10.51%, down 23.79% YoY. These metrics indicate significant profitability challenges.
Analyst sentiment is predominantly negative. Wells Fargo downgraded the stock to Equal Weight with a price target of $141, citing poor Q4 results and concerns over Medicaid pressures. Other firms, including Truist, JPMorgan, Goldman Sachs, Deutsche Bank, Barclays, TD Cowen, Cantor Fitzgerald, and UBS, have all lowered their price targets, with most maintaining Neutral or Hold ratings. The consensus reflects skepticism about the company's ability to meet its 2026 guidance.
